Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > By All Means A Wish To Make Algernon Pharmaceuticals Well...

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Apr 21, 2021 10:34am

205 Views

Post# 33036623

RE:By All Means A Wish To Make Algernon Pharmaceuticals Well...

Algernon/Bithorse :

You are a soup salad sandwich! Pumping this company on the way up, bashing it on the way down and then defending it in the dumpster!

Don't compare this heap with Bellus health who is run by Dr. Francesco Bellini who has a history of selling companies to big pharma. Bellus not only developed their own drug, they own all the patents! Both things Algernon can't say!

.03 more cents and I leave this board as promised

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale